Tag Archive for: Immuno-oncology

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

/in

Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]

Read more

NeoPhore appoints Michael Shih as Chief Executive Officer

/in

Highly experienced corporate development leader with a track record of international pharma and biotech deal-making New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as Chief Executive […]

Read more

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

/in

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment […]

Read more

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

/in

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

Read more

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

/in

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B […]

Read more
© Optimum Strategic Communications.